Software Revenue and Growth - Q4 2023 software revenue increased by 43.6% to $68.7 million compared to Q4 2022[5][7] - Full-year 2023 total revenue grew by 19.7% to $216.7 million, with software revenue up 17.4% to $159.1 million[9][13] - Software gross margin improved to 87% in Q4 2023 and 81% for the full year, up from 83% and 78% respectively in 2022[5][9] - Company expects 2024 software revenue growth of 6% to 13%, with Q1 2024 software revenue projected between $33 million and $35 million[1][16] - Software products and services revenue grew 17.4% to $159.124 million in 2023, up from $135.578 million in 2022[38] Annual Contract Value (ACV) and Customer Metrics - Total annual contract value (ACV) for software increased by 9.7% to $154.2 million in 2023, with Top 10 customers' ACV also up 9.7% to $51.0 million[12][15] - Number of customers with at least $1 million in ACV increased to 27 from 18 in 2022, while customers with at least $500,000 in ACV grew to 54 from 52[12][15] - Annual Contract Value (ACV) is tracked for each customer, with contracts billed annually or upfront, and is not a replacement for GAAP revenue[31] - Customer retention rate is calculated for customers with an ACV of at least $100,000 or $500,000, comparing active customers year-over-year[32] - Active customers are defined as those with an ACV of at least $1,000, excluding low-cost PyMOL software users[33] Drug Discovery Revenue - Drug discovery revenue for 2023 was $57.5 million, up 26.8% from 2022, driven by a $25.0 million milestone from BMS in Q1 2023[9][13] - Drug discovery revenue increased 26.8% to $57.542 million in 2023, compared to $45.377 million in 2022[38] Financial Performance and Profitability - Gross profit for 2023 was $140.692 million, a 39.3% increase from $101.022 million in 2022[38] - Net income attributable to Schrödinger common stockholders was $40.720 million in 2023, a significant improvement from a net loss of $149.186 million in 2022[38] - Net income for 2023 was $40.72 million, a significant improvement from a net loss of $149.19 million in 2022 and $101.22 million in 2021[42] - Non-GAAP net loss for 2023 was $157.76 million, compared to $142.86 million in 2022 and $90.40 million in 2021[43] - Net loss per share attributable to common stockholders for 2023 was $0.57 (basic) and $0.54 (diluted), compared to $2.10 (basic and diluted) in 2022 and $1.42 (basic and diluted) in 2021[43] Operating Expenses and R&D - Operating expenses for 2023 increased by 28.4% to $318.1 million, primarily due to higher R&D costs, with 2024 operating expense growth expected to range from 8% to 12%[9][18] Cash and Liquidity - Cash, cash equivalents, restricted cash, and marketable securities totaled $468.8 million at the end of 2023, down from $502.5 million at the end of Q3 2023 but up from $456.3 million at the end of 2022[13] - Cash and cash equivalents increased to $155.315 million in 2023, up from $90.474 million in 2022[40] - Total assets grew to $802.955 million in 2023, compared to $688.587 million in 2022[40] - Net cash used in operating activities for 2023 was $136.73 million, compared to $119.68 million in 2022 and $70.67 million in 2021[42] - Net cash provided by investing activities for 2023 was $193.03 million, a substantial increase from $90.02 million in 2022 and a net cash used of $16.81 million in 2021[42] - Net cash provided by financing activities for 2023 was $9.05 million, up from $2.11 million in 2022 and $7.95 million in 2021[42] - Cash and cash equivalents and restricted cash at the end of 2023 were $161.07 million, compared to $95.72 million at the end of 2022 and $123.27 million at the end of 2021[42] Clinical and Research Progress - Company anticipates initial data readouts from its first two patient studies in late 2024 or 2025 and plans to progress a third program to the clinic in 2024[3][22] Share Metrics - Weighted average shares used to compute net loss per share for 2023 were 71.78 million (basic) and 74.99 million (diluted), compared to 71.17 million (basic and diluted) in 2022 and 70.59 million (basic and diluted) in 2021[43]

Wall Street analysts expect Schrodinger, Inc. (SDGR) to post quarterly loss of $0.44 per share in its upcoming report, which indicates a year-over-year decline of 12.8%. Revenues are expected to be $77.8 million, up 36.9% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnings ...

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in March: TD Cowen 44th Annual Health Care Conference: Fireside chat on Tuesday, March 5, 2024 at 10:30 a.m. ET. Leerink Partners Global Biopharma Conference: Fireside chat on Monday, March 11, 2024 at 12:40 p.m. E.T. KeyBanc Life Sciences & MedTech Forum (Virtua ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2024, the company granted (i) non-statutory stock options to purchase 6,825 shares of the company’s common stock to seven newly hired employees and (ii) restricted stock units (RSUs) with respect to 8,438 shares of the company’s common stock to 15 newly hired employees. These grants were made pursuant to ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024. Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company. The three-year agreement builds on the collaboration established in 2022. The agreement ...

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Ramy Farid - President and Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies LLC Malcolm Hoffman - BMO Capital Markets Michael Ryskin - Bank of America Securities, Inc. Matthew Hewitt - Craig- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 _____________________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies David Lebowitz - Citigroup Evan Seigerman - BMO Capital Markets Vikram Purohit - Morgan Stanley Matt Hewitt - Craig-Hallum Gaurav Goparaju - Berenberg Capital Markets Michael Ryskin - Bank of America Joseph Catanzaro - Pip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to (Mark One) Commission File Number: 001-39206 ________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR WASHINGTON, DC 20549 ________________________________________ Schrodinger, Inc. o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q ________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Vikram Purohit - Morgan Stanley David Lebowitz - Citi Chris Shibutani - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. Welcome to Schr ...